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Background: Small coronary artery disease is a recognised challenging subset within the field of coronary artery intervention. Fully bioresorbable 
drug-eluting vascular scaffolds (BVS, Abbott Vascular, Santa Clara, USA) are a novel approach to treating coronary lesions and are untested in small 
vessels. We investigate the six month clinical outcomes after implantation of a second generation 3mm BVS in small coronary vessels (<2.5mm)
Methods: The ABSORB cohort B Trial is a multicentre single-arm, prospective, open-label trial in which 101 patients were enrolled. Within this 
study the vessel size was overestimated, by visual assessment of the operator, in 41 patients prior to implantation of a 3mm BVS in vessels with 
a pre-procedural reference vessel diameter (RVD) of <2.5mm. The pre-RVD was assessed by quantitative coronary angiography (QCA) during post-
hoc analysis. The study population was therefore divided into two groups, group I (41 patients) with RVD <2.5mm and group II (60 patients) with 
RVD ≥2.5 mm. The composite endpoint of ischaemia-driven major adverse cardiac events (ID-MACE), defined as ischemia-driven target lesion 
revascularization (ID-TLR), in-scaffold thrombosis, myocardial infarction (MI) or cardiac death, were assessed. Out of the 45 patients initially enrolled 
for 6 month coronary angiography, 42 patients had the procedure performed with IVUS undertaken in 40 of these patients.
Results: At 6 months no significant differences in ID-MACE (3/41, 7.3% vs. 2/60 cases, 3.3% p=0.3933) were observed in small and large 
vessel groups respectively. No cardiac deaths or episodes of in-scaffold thromboses were seen. Angiographic and IVUS follow-up demonstrated no 
differences in late lumen loss (0.16±0.18mm vs. 0.21±0.17mm, p=0.35) or percentage lumen area stenosis (17.6±6.0% vs. 19.8±8.5%, p=0.3643).
Conclusions: The second generation 3mm BVS appeared to be safe in small vessels with similar clinical and angiographic outcomes as large 
vessels. Results of the large scale Absorb Extend registry are awaited
